CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N. Shah, Terry J. Fry, Steven L. Highfill et al.|Journal of Clinical Oncology|2020Cited by 422
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cellsDaniel A. Lichtenstein, Nirali N. Shah, Fiorella Schischlik et al.|Blood|2021Cited by 194
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARHaneen Shalabi, Nirali N. Shah, Sara Silbert et al.|Blood|2022Cited by 179
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphomaHaneen Shalabi, Nirali N. Shah, Ira L. Kraft et al.|Haematologica|2018Cited by 171
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J. Lamble, Nirali N. Shah, Regina M. Myers et al.|Blood Advances|2022Cited by 149